Video Series
Role of Systemic Therapy in TACE-Eligible Patients
March 10th 2025The panelist discusses how for patients initially eligible for embolization, systemic therapy may be combined with transarterial chemoembolization (TACE) upfront for high-risk disease (ie, large tumor burden, elevated AFP) or reserved for progression after regional therapy in lower-risk cases. Treatment decisions should be individualized based on tumor characteristics, liver function, and patient preferences.
Symptom Burden and Quality of Life: Centering the PV Patient Experience
March 10th 2025A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care approaches for patients with polycythemia vera (PV) by providing critical insights into symptom burden, quality-of-life impacts, and treatment effectiveness that might otherwise go unrecognized through standard clinical assessments alone.
Managing Disease Progression After TACE
March 10th 2025The panelist discusses how the patient underwent transarterial chemoembolization (TACE) 3 times with an initial partial response. However, at the end of the 6-month treatment period, the patient had disease progression. The panelist advises that the best treatment option for the patient would be systemic therapy.
Molecular Monitoring Advances in PV Disease Assessment and Management
March 10th 2025A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by providing quantifiable markers for tracking mutation burden, treatment response, and risk stratification that complement traditional clinical parameters.
Understanding BPDCN: From Disease Presentation to Diagnosis
March 7th 2025An expert discusses how blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy derived from plasmacytoid dendritic cell precursors, presenting with skin lesions, lymphadenopathy, and bone marrow involvement. For a man aged 62 years, key concerns include rapid progression, immunophenotypic complexity, and potential misdiagnosis. Diagnostic challenges arise from its rarity and overlapping features with other hematologic disorders. Improved outcomes require multidisciplinary teams, standardized testing protocols, and specialized referral centers.
A 62-Year-Old Man Who Is Newly Diagnosed With BPDCN
March 7th 2025An expert discusses the patient case of a man aged 62 years who is newly diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The patient initially presented to the dermatologist with a progressive and persistent rash notable for bumps and nodules. The nodules presented a violet-like color, beginning on his forehead and spreading to the rest of his body.
KarMMa-3 Trial: Additional Insights From Ide-Cel in RRMM
March 7th 2025Panelists discuss how detailed analyses from KarMMa-3 reveal key insights about ide-cel’s performance across patient subgroups, timing of responses, durability of remissions, and management of adverse effects in relapsed/refractory multiple myeloma (RRMM).
KarMMa-3 Highlights: Ide-Cel vs Standard Regimens in Triple-Class– Exposed RRMM
March 7th 2025Panelists discuss how the KarMMa-3 trial demonstrated superior efficacy of idecabtagene vicleucel (ide-cel) chimeric antigen receptor T-cell therapy compared to standard treatment regimens in patients with heavily pretreated, triple-class–exposed relapsed/refractory multiple myeloma (RRMM).
Sequencing Through Multiple Lines of Therapy for mRCC
March 6th 2025A panelist discusses how treatment sequencing decisions in RCC span multiple lines of therapy, incorporating various options like tivozanib, lenvatinib-everolimus combinations, and belzutifan, with careful consideration given to optimal dosing strategies, expected duration of therapy, anticipated response patterns, and the specific timing of each agent in the treatment journey, particularly in the post-ICI setting.
Case (cont.): Dr Pal’s Approach Toward 2L Therapy Selection
March 6th 2025A panelist discusses how second-line therapy selection in metastatic RCC requires careful consideration of multiple factors including prior treatment response, individual patient characteristics, specific drug properties (such as mechanism of action and pharmacokinetics), strength of clinical evidence, and practical considerations like tolerability and quality of life, while acknowledging current evidence gaps and unmet needs in the post-ICI treatment landscape.
A Review of Current and Emerging Clinical Data for 3L mRCC
March 4th 2025An expert discusses how efficacy and safety data from trials such as METEOR, TIVO-3, TiNivo-2, and LITESPARK-005 guide third line (3L) renal cell carcinoma (RCC) treatment. Differences in trial populations, evolving long-term trends, and prior immune checkpoint inhibitor (ICI) use impact applicability. CONTACT-03 and TiNivo-2 provide key insights, and real-world data and patient-reported outcomes refine clinical decision-making. Community oncologists should critically assess study limitations and evolving evidence when selecting therapy.
Recent Advances in Front-Line Systemic Therapy for Advanced uHCC
March 4th 2025An expert discusses how first-line (1L) systemic therapy for unresectable hepatocellular carcinoma (uHCC) has evolved significantly from sorafenib monotherapy to include combination approaches such as atezolizumab plus bevacizumab, which demonstrated superior outcomes in the IMbrave150 trial. Key challenges include underlying liver dysfunction, heterogeneous tumor biology, and managing adverse events while preserving quality of life. Treatment goals focus on extending survival while maintaining liver function and performance status. The shift toward immunotherapy-based combinations has improved outcomes, though patient selection and sequencing strategies remain important considerations in optimizing first-line treatment decisions in clinical practice.
Third-Line Treatments and Current Practice Guidelines in Advanced RCC
March 4th 2025A panelist discusses how, based on the NCCN guidelines for kidney cancer, third-line treatment options for this patient include cabozantinib, lenvatinib plus everolimus, tivozanib, and everolimus monotherapy. Clinical trials and best supportive care remain important considerations at this stage.
A 57-Year-Old Woman Diagnosed with Advanced Unresectable Hepatocellular Carcinoma
March 4th 2025An expert discusses the patient case of a 57-year-old woman diagnosed with advanced unresectable hepatocellular carcinoma. The patient presented with abdominal pain, fatigue, and loss of appetite. She also has a history of Crohn disease, which is being controlled with infliximab. The patient also has a history of variceal bleeding and has been treated with antiviral therapy for chronic hepatitis B virus infection.
Integrating Molecular Profiles Into PV-Specific Treatment Planning
March 3rd 2025A panelist discusses how a patient’s initial presentation and molecular profile guide personalized treatment approaches for polycythemia vera (PV), weighing factors such as symptom burden, risk stratification, and genetic markers to optimize therapeutic outcomes.
Evolving Treatment Landscape: Integrating New Evidence Into Clinical Practice
March 3rd 2025Panelists discuss how recent clinical trial data and emerging therapeutic options are reshaping the treatment paradigm for myelofibrosis, requiring thoughtful integration of new evidence into current clinical practice guidelines.
Key Updates From TALAPRO-2 Presented at ASCO 2025
February 28th 2025Panelists discuss how recent clinical data presented at ASCO 2025 showed varying results across primary endpoints including overall survival, progression-free survival, efficacy measures, and safety profiles, with key opinion leaders highlighting implications for current treatment paradigms.
